Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant ...

GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets. 2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, ...